These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 1999776)

  • 1. High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell disease.
    Wang WC; Kovnar EH; Tonkin IL; Mulhern RK; Langston JW; Day SW; Schell MJ; Wilimas JA
    J Pediatr; 1991 Mar; 118(3):377-82. PubMed ID: 1999776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography.
    Adams RJ; McKie VC; Hsu L; Files B; Vichinsky E; Pegelow C; Abboud M; Gallagher D; Kutlar A; Nichols FT; Bonds DR; Brambilla D
    N Engl J Med; 1998 Jul; 339(1):5-11. PubMed ID: 9647873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions.
    Pegelow CH; Adams RJ; McKie V; Abboud M; Berman B; Miller ST; Olivieri N; Vichinsky E; Wang W; Brambilla D
    J Pediatr; 1995 Jun; 126(6):896-9. PubMed ID: 7776091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less intensive long-term transfusion therapy for sickle cell anemia and cerebrovascular accident.
    Miller ST; Jensen D; Rao SP
    J Pediatr; 1992 Jan; 120(1):54-7. PubMed ID: 1731025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of transfusion therapy for one to two years in patients with sickle cell disease and cerebrovascular accidents.
    Wilimas J; Goff JR; Anderson HR; Langston JW; Thompson E
    J Pediatr; 1980 Feb; 96(2):205-8. PubMed ID: 7351580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stroke prevention trial in sickle cell anemia.
    Adams RJ; McKie VC; Brambilla D; Carl E; Gallagher D; Nichols FT; Roach S; Abboud M; Berman B; Driscoll C; Files B; Hsu L; Hurlet A; Miller S; Olivieri N; Pegelow C; Scher C; Vichinsky E; Wang W; Woods G; Kutlar A; Wright E; Hagner S; Tighe F; Waclawiw MA
    Control Clin Trials; 1998 Feb; 19(1):110-29. PubMed ID: 9492971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of long-term transfusion therapy in patients with sickle cell disease and stroke.
    Rana S; Houston PE; Surana N; Shalaby-Rana EI; Castro OL
    J Pediatr; 1997 Nov; 131(5):757-60. PubMed ID: 9403661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia.
    DeBaun MR; Gordon M; McKinstry RC; Noetzel MJ; White DA; Sarnaik SA; Meier ER; Howard TH; Majumdar S; Inusa BP; Telfer PT; Kirby-Allen M; McCavit TL; Kamdem A; Airewele G; Woods GM; Berman B; Panepinto JA; Fuh BR; Kwiatkowski JL; King AA; Fixler JM; Rhodes MM; Thompson AA; Heiny ME; Redding-Lallinger RC; Kirkham FJ; Dixon N; Gonzalez CE; Kalinyak KA; Quinn CT; Strouse JJ; Miller JP; Lehmann H; Kraut MA; Ball WS; Hirtz D; Casella JF
    N Engl J Med; 2014 Aug; 371(8):699-710. PubMed ID: 25140956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease.
    Russell MO; Goldberg HI; Hodson A; Kim HC; Halus J; Reivich M; Schwartz E
    Blood; 1984 Jan; 63(1):162-9. PubMed ID: 6689947
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A modified transfusion program for prevention of stroke in sickle cell disease.
    Cohen AR; Martin MB; Silber JH; Kim HC; Ohene-Frempong K; Schwartz E
    Blood; 1992 Apr; 79(7):1657-61. PubMed ID: 1558963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of total hemoglobin and hemoglobin S concentration on cerebral blood flow during transfusion therapy to prevent stroke in sickle cell disease.
    Hurlet-Jensen AM; Prohovnik I; Pavlakis SG; Piomelli S
    Stroke; 1994 Aug; 25(8):1688-92. PubMed ID: 8042222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.
    Adams RJ; Brambilla D;
    N Engl J Med; 2005 Dec; 353(26):2769-78. PubMed ID: 16382063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased blood requirements during long-term transfusion therapy for sickle cell disease.
    Cohen AR; Buchanan GR; Martin M; Ohene-Frempong K
    J Pediatr; 1991 Mar; 118(3):405-7. PubMed ID: 1999779
    [No Abstract]   [Full Text] [Related]  

  • 14. Transcranial Doppler, MRA, and MRI as a screening examination for cerebrovascular disease in patients with sickle cell anemia: an 8-year study.
    Seibert JJ; Glasier CM; Kirby RS; Allison JW; James CA; Becton DL; Kinder DL; Cox KS; Flick EL; Lairry F; Jackson JF; Graves RA
    Pediatr Radiol; 1998 Mar; 28(3):138-42. PubMed ID: 9561529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease.
    Mirre E; Brousse V; Berteloot L; Lambot-Juhan K; Verlhac S; Boulat C; Dumont MD; Lenoir G; de Montalembert M
    Eur J Haematol; 2010 Mar; 84(3):259-65. PubMed ID: 19912310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential cerebral hemometabolic responses to blood transfusions in adults and children with sickle cell anemia.
    Juttukonda MR; Lee CA; Patel NJ; Davis LT; Waddle SL; Gindville MC; Pruthi S; Kassim AA; DeBaun MR; Donahue MJ; Jordan LC
    J Magn Reson Imaging; 2019 Feb; 49(2):466-477. PubMed ID: 30324698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.
    Scothorn DJ; Price C; Schwartz D; Terrill C; Buchanan GR; Shurney W; Sarniak I; Fallon R; Chu JY; Pegelow CH; Wang W; Casella JF; Resar LS; Berman B; Adamkiewicz T; Hsu LL; Ohene-Frempong K; Smith-Whitley K; Mahoney D; Scott JP; Woods GM; Watanabe M; Debaun MR
    J Pediatr; 2002 Mar; 140(3):348-54. PubMed ID: 11953734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moyamoya syndrome in childhood sickle cell disease: a predictive factor for recurrent cerebrovascular events.
    Dobson SR; Holden KR; Nietert PJ; Cure JK; Laver JH; Disco D; Abboud MR
    Blood; 2002 May; 99(9):3144-50. PubMed ID: 11964276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia.
    Bishop S; Matheus MG; Abboud MR; Cane ID; Adams RJ; Jackson SM; Kalpatthi R
    Blood Cells Mol Dis; 2011 Aug; 47(2):125-8. PubMed ID: 21724428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
    Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
    J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.